StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for DNLI yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $18.39 | $18.11 | -1.52% | 2.1M |
| 05-20 | $18.21 | $18.83 | +3.40% | 1.4M |
| 05-21 | $18.55 | $19.30 | +4.04% | 1.4M |
| 05-22 | $18.52 | $18.64 | +0.65% | 3.6M |
| 05-26 | $18.86 | $19.31 | +2.39% | 1.6M |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-555.34M | $-487.34M | $-357.50M | $-234.31M |
Net Income | $-512.54M | $-422.77M | $-308.02M | $-200.83M |
EPS (Diluted) | $-2.97 | $-2.57 | $-1.89 | $-1.26 |
Total Assets | $1.14B | $1.37B | $1.45B | $1.50B |
Total Liabilities | $131.09M | $144.50M | $135.52M | $115.51M |
Cash & Equivalents | $205.33M | $174.96M | $90.64M | $74.68M |
Free Cash Flow OCF − CapEx | $-422.10M | $-363.61M | $-274.80M | $-211.78M |
Shares Outstanding | 156.18M | 144.22M | 143.84M | 143.12M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.